Comparative Evaluation of Lercanidipine and Amlodipine in Hypertensive Patients: Efficacy, Tolerability, and the Role of Gut Microbiota Modulation
Keywords:
Hypertension, Lercanidipine, Amlodipine, Blood Pressure, Tolerability, Gut Microbiota, Calcium Channel BlockersAbstract
Background: Hypertension affects over 1.28 billion adults globally and is a major contributor to cardiovascular morbidity and mortality. Calcium channel blockers, such as lercanidipine and amlodipine, are widely prescribed for hypertension management, yet their differential impact on gut microbiota remains underexplored.
Objective: This study aimed to compare the efficacy, tolerability, and microbiota-modulating effects of lercanidipine versus amlodipine in hypertensive patients over a 12-month period.
Methods: A randomized, open-label clinical trial was conducted at three tertiary care hospitals in Peshawar, Pakistan, involving 320 adults with essential hypertension. Participants were randomly assigned to receive either lercanidipine 10 mg or amlodipine 5 mg once daily. Blood pressure was monitored monthly, and treatment adherence, adverse effects, and gut microbiota changes were assessed. Stool samples were collected at baseline and after 12 months for 16S rRNA sequencing. Statistical comparisons were made using t-tests, ANOVA, and Kaplan–Meier survival analysis.
Results: Both groups exhibited significant reductions in systolic and diastolic blood pressure, with lercanidipine achieving target levels faster (4.2 vs. 5.6 weeks). Lercanidipine was associated with higher adherence (92% vs. 85%) and fewer cases of peripheral edema (5% vs. 12%). Gut microbiota analysis revealed that lercanidipine preserved alpha diversity and enriched beneficial genera such as Faecalibacterium and Lactobacillus, whereas amlodipine led to decreased diversity and an increase in Escherichia/Shigella abundance.
Conclusion: Both drugs work well to lower blood pressure, yet lercanidipine has a better chance of tolerance, quicker action on blood pressure and helps improve gut bacteria. These findings suggest its potential as a preferable choice in personalized hypertension management, participating microbial health consideration.
Downloads
Metrics
References
World Health Organization. (2021). Hypertension. https://www.who.int/news-room/fact-sheets/detail/hypertension
Zhou, B., et al. (2021). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: A pooled analysis of 1201 population-representative studies with 104 million participants. The Lancet, 398(10304), 957–980. https://doi.org/10.1016/S0140-6736(21)01330-1
Mills, K. T., Stefanescu, A., & He, J. (2020). The global epidemiology of hypertension. Nature Reviews Nephrology, 16(4), 223–237. https://doi.org/10.1038/s41581-019-0244-2
Khan, M. S., et al. (2023). Projected burden of hypertension in Pakistan: 2020–2040. BMC Public Health, 23, 16662. https://doi.org/10.1186/s12889-023-16662-z
Messerli, F. H., Bangalore, S., & Bavishi, C. (2021). Calcium channel blockers in hypertension: To use or not to use? Current Cardiology Reports, 23(7), 75. https://doi.org/10.1007/s11886-021-01498-5
Lacourcière, Y., & Asmar, R. (2021). Amlodipine and lercanidipine: Comparative pharmacology and efficacy. Journal of Clinical Hypertension, 23(11), 1942–1949. https://doi.org/10.1111/jch.14257
Chobanian, A. V. (2023). Clinical utility of amlodipine in hypertension management. American Journal of Hypertension, 36(2), 123–130. https://doi.org/10.1093/ajh/hpad015
Weir, M. R. (2022). Adverse effects of antihypertensive therapy: A focus on amlodipine. Drugs, 82(1), 51–58. https://doi.org/10.1007/s40265-021-01614-2
Ghosh, A., & Basu, A. (2023). Safety and side effects of calcium channel blockers. Expert Review of Clinical Pharmacology, 16(2), 145–153. https://doi.org/10.1080/17512433.2023.2161675
Malacco, E., et al. (2023). Pharmacological profile and vascular selectivity of lercanidipine. Journal of Hypertension, 41(4), 678–684. https://doi.org/10.1097/HJH.0000000000003243
Chen, J., et al. (2022). Tolerability of lercanidipine in the elderly: A meta-analysis. Drugs & Aging, 39(3), 215–222. https://doi.org/10.1007/s40266-022-00901-5
Barrios, V., et al. (2023). Comparative study of lercanidipine versus amlodipine: TOLERANCE trial results. European Heart Journal Supplements, 25(Suppl A), A35–A42. https://doi.org/10.1093/eurheartj/suad018
Yang, T., et al. (2023). Role of gut microbiota in hypertension: Recent advances. Hypertension Research, 46(2), 233–245. https://doi.org/10.1038/s41440-022-00975-0
Li, J., et al. (2023). Gut microbiota and hypertension: Association and mechanisms. Journal of Human Hypertension, 37(1), 1–10. https://doi.org/10.1038/s41371-022-00706-5
Gao, Y., et al. (2023). Gut microbiota composition in hypertension: A systematic review. Frontiers in Cardiovascular Medicine, 10, 1333005. https://doi.org/10.3389/fcvm.2023.1333005
Liu, Y., et al. (2023). Role of gut microbiota in drug metabolism and hypertension therapy. Pharmacological Research, 186, 106511. https://doi.org/10.1016/j.phrs.2022.106511
Wang, Y., et al. (2023). Gut microbiota: A potential new regulator of blood pressure. Frontiers in Nutrition, 10, 1253803. https://doi.org/10.3389/fnut.2023.1253803
Chen, Y., et al. (2023). Gut microbiota and antihypertensive medications: Clinical implications. Journal of Translational Medicine, 21(1), 140. https://doi.org/10.1186/s12967-023-04092
Zhang, Y., et al. (2023). Microbial dysbiosis in hypertensive patients: Evidence from a meta-analysis. Journal of Clinical Hypertension, 25(3), 234–245. https://doi.org/10.1111/jch.14632
De Caterina, R., et al. (2024). Comparative effectiveness of lercanidipine and amlodipine in essential hypertension: A real-world study. American Journal of Hypertension, 37(1), 34–41. https://doi.org/10.1093/ajh/hpad059
Sica, D. A., & Gehr, T. W. (2023). Clinical comparison of calcium channel blockers: Focus on tolerability. Cardiology Clinics, 41(1), 95–104. https://doi.org/10.1016/j.ccl.2022.08.006
Barrios, V., et al. (2023). TOLERANCE study: Efficacy and tolerability of lercanidipine vs amlodipine in hypertension management. European Heart Journal Supplements, 25(Suppl A), A35–A42. https://doi.org/10.1093/eurheartj/suad018
Burnier, M., & Egan, B. M. (2023). Adherence in hypertension: A review of current evidence. Hypertension Research, 46(5), 891–899. https://doi.org/10.1038/s41440-022-00988-9
Marques, F. Z., et al. (2023). The gut microbiome and hypertension: Mechanistic insights and clinical implications. Nature Reviews Cardiology, 20(4), 227–241. https://doi.org/10.1038/s41569-022-00789-y
Rehman, A., et al. (2024). Hypertension and the gut microbiome: The effect of antihypertensive therapy on microbial communities. Trends in Cardiovascular Medicine, 34(1), 45–53. https://doi.org/10.1016/j.tcm.2023.08.005
Qi, Y., et al. (2023). Gut microbiota modulates blood pressure via metabolic and inflammatory pathways. Circulation Research, 132(6), 756–773. https://doi.org/10.1161/CIRCRESAHA.122.320275
Shapiro, H., et al. (2023). The link between microbial diversity and cardiovascular health. Frontiers in Cardiovascular Medicine, 10, 1249009. https://doi.org/10.3389/fcvm.2023.1249009
Pluznick, J. L. (2023). A new frontier in hypertension: Gut microbiota and host response. Hypertension, 81(3), 532–540. https://doi.org/10.1161/HYPERTENSIONAHA.122.19609
Wang, L., et al. (2023). Personalized medicine in hypertension: Role of gut microbiota. Clinical Research in Cardiology, 112(4), 387–397. https://doi.org/10.1007/s00392-022-02089-3
Valles-Colomer, M., et al. (2024). Drug–microbiome interactions in cardiovascular pharmacology. Nature Microbiology, 9(2), 183–192. https://doi.org/10.1038/s41564-024-01345-x
de la Cuesta-Zuluaga, J., et al. (2023). Microbiota and hypertension: Dysbiosis as a contributor to poor blood pressure control. Journal of Hypertension, 41(3), 390–398. https://doi.org/10.1097/HJH.0000000000003297
Koeth, R. A., et al. (2023). Limitations of 16S rRNA sequencing in characterizing functional gut microbiota changes in hypertension. Journal of Microbiological Methods, 207, 106636. https://doi.org/10.1016/j.mimet.2023.106636
Nasreddine, L., et al. (2024). Regional differences in gut microbiota and implications for hypertension therapy. Journal of Clinical Hypertension, 26(1), 66–74. https://doi.org/10.1111/jch.14582
Khan, T. J., et al. (2023). Metabolomics of hypertension: The role of gut microbial metabolites. Metabolites, 13(9), 1022. https://doi.org/10.3390/metabo13091022
Kelly, T. N., et al. (2023). The need for global inclusion in hypertension microbiome trials. Global Heart, 18(1), 24. https://doi.org/10.5334/gh.1262
Yan, Q., et al. (2024). Preclinical models of gut microbiota interactions with antihypertensive drugs. Current Hypertension Reports, 26(2), 98–106. https://doi.org/10.1007/s11906-024-01294-7
Arora, P., et al. (2023). Precision hypertension care: Incorporating gut microbiota in risk stratification. Trends in Pharmacological Sciences, 44(12), 912–922. https://doi.org/10.1016/j.tips.2023.07.002.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
